In brief: ChemGenex Pharmaceuticals, Novogen, Peptech

ChemGenex Pharmaceuticals (ASX:CXS) has received approval to list on the NASDAQ SmallCap Market under the ticker CXSP. Trading in the company's American Depositary Receipts (ADR) will be possible from June 28. Each ADR will represent 15 ordinary shares on the ASX.

Novogen (ASX:NRT, NASDAQ:NVGN) has been granted three Australian health supplement patents covering tablets or capsules containing any two of the four main isoflavones: biochanin, formononetin, diadzein and genistein. The patents directly benefit the company's health products Promensil, a natural menopause supplement, and Trinovin, a supplement for prostate health in men, and are in place till 2013.

Peptech's (ASX:PTD) joint venture partner Biosceptre International has been granted an Australian patent related to the diagnostic use of antibodies binding a cancer cell marker in addition to equivalent patents already granted in South Africa, New Zealand and Singapore.